/C O R R E C T I O N -- Rheingold, Valet, Rheingold, McCartney & Giuffra LLP/

/C O R R E C T I O N -- Rheingold, Valet, Rheingold, McCartney & Giuffra LLP/

PR Newswire

NEW YORK, June 14, 2013

In the news release, Suit filed for Pancreatic Cancer By Use of Byetta,
Januvia and Janumet, issued 17-Jun-2013 by Rheingold, Valet, Rheingold,
McCartney & Giuffra LLP over PR Newswire, the source was originally
transmitted incorrectly as Rheingold, Valet, Rheingold, Shkolnik & McCartney
LLP. The source should read: Rheingold, Valet, Rheingold, McCartney & Giuffra
LLP. Also, the client has advised us to the following changes: The first
paragraph went out as "The law firm of Rheingold, Valet, Rheingold, McCartney
& Giuffra LLP has just commenced what is believed to be the first suit in New
York for the development of pancreatic cancer in the user of two common
anti-diabetic drugs, Byetta and Janumet (also known as Januvia). The suit, by
Staten Island resident Robert Cataletto, was filed on June 14, 2013 Cataletto
v. Amylin Pharmaceuticals, LLC, et al., E.D.N.Y. CV 13-3411." This paragraph
should read "The law firm of Rheingold, Valet, Rheingold, McCartney & Giuffra
LLP has just commenced what is believed to be the first suit in New York for
the development of pancreatic cancer in the user of three common anti-diabetic
drugs: Byetta, Januvia and Janumet. The suit, by Staten Island resident Robert
Cataletto, was filed on June 14, 2013, and it is captioned Cataletto v. Amylin
Pharmaceuticals, LLC, et al., E.D.N.Y. 13-cv-3411." The last sentence in the
seventh paragraph went out as "It is currently heavily involved with
litigation involving metal-on-metal hips made by DePuy and Stryker." This
sentence should read "It is currently heavily involved with litigation
involving metal-on-metal hips made by Biomet, DePuy, Stryker and Wright
Medical, all of which have genotoxic galvanic reactions known to be
carcinogenic." The complete, corrected release follows:

  Suit filed for Pancreatic Cancer By Use of Byetta, Januvia and Janumet

NEW YORK, June 17, 2013 /PRNewswire/ -- The law firm of Rheingold, Valet,
Rheingold, McCartney & Giuffra LLP has just commenced what is believed to be
the first suit in New York for the development of pancreatic cancer in the
user of three common anti-diabetic drugs: Byetta, Januvia and Janumet. The
suit, by Staten Island resident Robert Cataletto, was filed on June 14, 2013,
and it is captioned Cataletto v. Amylin Pharmaceuticals, LLC, et al., E.D.N.Y.
13-cv-3411.

Mr. Cataletto received prescriptions from the doctor attending to his adult
diabetes condition in the period from 2009 to 2012 for Byetta and Janumet.
Byetta, manufactured by Merck, Inc., has been on the market since 2005 and is
known as a glucagen-like peptide. It treats diabetes by preventing a build-
up of sugar in the body.

Junuvia is made by Amylin Pharmaceuticals LLC, a company recently bought by
Bristol Myers Squibb Co. First marketed in 2007, it in the category of a
dipeptidyl-peptidase-4 drug, which also reduces blood glucose levels. When
combined with an older drug, metformin, the drug is known as Janumet. The
broader category for the drugs involved in this law suit is known as
"incretins."

The complaint which was just filed alleges that the manufacturers of both of
these products were alerted starting in 2010 that there was an increased
incidence of pancreatic cancer in users of these drugs as compared to
diabetics treated with the older, more proven forms of treatment. The notice
also came from the German Medical Association and a petition by Public
Citizen, a non-profit health group in Washington.

There have been similar reports of a sharp increase in
pancreatitis—inflammation of the pancreas gland—in users of these same drugs.
The complaint alleges that pancreatitis may be a forerunner of pancreatic
cancer. Pancreatic cancer is among the deadliest of all cancers, for which
there are no satisfactory treatments.

The complaint charges that the defendants were aware of the serious health
risks associated with the use of these drugs, and concealed them from the
public, prescribing doctors and governmental regulatory bodies. It not only
seeks damages for the pain and suffering and economic loss sustained by the
Cataletto family but also punitive or punishment damages based on "disregard
for human life."

"From our examination of the data, it appears to us that there has been over
promotion and under warning by the sellers of these and other drugs in the
incretin category," says Paul D. Rheingold, senior partner in the law firm.
The firm specializes in representing persons injured by drugs and medical
devices. It is currently heavily involved with litigation involving
metal-on-metal hips made by Biomet, DePuy, Stryker and Wright Medical, all of
which have genotoxic galvanic reactions known to be carcinogenic.

Attention is also being directed now to other drugs in the incretin category,
including Victorza and Onglyza. The manufacturers of all of these drugs
announced in mid-June that they would cooperate with the Food and Drug
Administration and the American Diabetes Association in studying the potential
link between use of incretins and the development of pancreatic cancer.

For more information please visit our website www.rheingoldlaw.comor contact
our firm
Rheingold, Valet, Rheingold, McCartney & Giuffra LLP
113 East 37^th Street, New York, NY 10016
Tel. No.: 1(800)349-0004/(212)684-1880



SOURCE Rheingold, Valet, Rheingold, McCartney & Giuffra LLP

Website: http://www.rheingoldlaw.com